We've updated our Privacy Policy to make it clearer how we use your personal data.
We use cookies to provide you with a better experience, read our Cookie Policy
EP39914
Abstract: The present scenario of the Pharmaceutical companies demands to develop to a better and novel therapeutics for coping up with their maintenance of profit, global economy, losses from patients death, and challenges from generic manufacturers. As a result they aims for m iniaturization. Nanotechnology can be strategically implemented in the new developing drug delivery system that can expand the drug markets. A budding interest in nanopharmaceuticals has generated a number of advancements throughout recent years with a focus on engineering novel applications. Nanotechnology is practically a therapeutics containing nanomaterials that has unique properties compared to their bulk phase counterparts. Nanopharmaceuticals present novel reformulation opportunities for active agents (e.g., single molecule drugs, proteins, nucleic acids, etc.) that were previously insoluble or could not be targeted to a specific site of the body where they were needed (such as the Blood Brain Barrier). Nanotechnology also offers the ability to detect diseases at much earlier stages, such as finding hidden or overt metastatic colonies often seen in patients diagnosed with breast, lung, colon, prostate, and ovarian cancer. Diagnostic applications could build upon conventional procedures using nanoparticles, such as colloidal gold, iron oxide crystals, and quantum dots. Nanopharmaceuticals can also increase the half life of the drug by increasing the immunogenicity and drug metabolism, enhance bioavailability. With all these benefits nanopharmaceuticals is expected to extend drug’s lifetime, enhancing the performance of drugs, safety and patient adherence, and ultimately reducing healthcare costs. A large number of US FDA approved nanopharmaceuticals are already been launched while some are still under various clinical trials.Summary: The present scenario of the Pharmaceutical companies demands to develop to a better and novel therapeutics for coping up with their maintenance of profit, global economy, losses from patients death, and challenges from generic manufacturers.Nanotechnology also offers the ability to detect diseases at much earlier stages, such as finding hidden or overt metastatic colonies often seen in patients diagnosed with breast, lung, colon, prostate, and ovarian cancer. References: Pharma Times, Official Monthly Magazine Of Indian Pharmaceutical Association (IPA)
https://ipapharma.org/about-pharma-times/
https://ipapharma.org/about-pharma-times/
Ask the author a question about this poster.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Related Posters
Quantitative systems pharmacology modeling of immune response role in Parkinson’s disease
Tatiana Karelina, Olga Ivanova, Oleg Demin
Composition Analysis Case Study
Tylor
Catalysts for Hydrogen Storage
Tylor
Necrobiose Lipóidica: a importância de a saber reconhecer
Maria Beatriz Morgado
Pharmacokinetics modeling and optimal dose prediction for a bispecific antibody against CD40 and PD1
Alexandra Diakonova, Oleg Demin Jr, Dmitry Shchelokov, Oleg Demin
